Tenax Therapeutics Ownership

TENX Stock  USD 5.94  0.29  5.13%   
The market capitalization of Tenax Therapeutics is $19.24 Million. 30% of Tenax Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
1996-09-30
Previous Quarter
M
Current Value
21.2 M
Avarage Shares Outstanding
556.8 K
Quarterly Volatility
3.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Tenax Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tenax Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividends Paid is likely to rise to about 8.9 M in 2024, whereas Dividend Yield is likely to drop 3.31 in 2024. Common Stock Shares Outstanding is likely to rise to about 260.9 K in 2024, despite the fact that Net Loss is likely to grow to (27.8 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Tenax Stock Ownership Analysis

About 48.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tenax Therapeutics recorded a loss per share of 13.05. The entity last dividend was issued on the 26th of February 2018. The firm had 1:80 split on the 3rd of January 2024. Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. Tenax Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Tenax Therapeutics contact Christopher Giordano at (919) 855-2100 or learn more at https://www.tenaxthera.com.
Besides selling stocks to institutional investors, Tenax Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tenax Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tenax Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Tenax Therapeutics Quarterly Liabilities And Stockholders Equity

99.78 Million

Tenax Therapeutics Insider Trades History

Less than 1% of Tenax Therapeutics are currently held by insiders. Unlike Tenax Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tenax Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tenax Therapeutics' insider trades
 
Credit Downgrade
 
Yuan Drop
 
Covid

Tenax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tenax Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tenax Therapeutics backward and forwards among themselves. Tenax Therapeutics' institutional investor refers to the entity that pools money to purchase Tenax Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-09-30
18.4 K
Tower Research Capital Llc2024-09-30
1.7 K
Ubs Group Ag2024-09-30
688
Blackrock Inc2024-06-30
300
Morgan Stanley - Brokerage Accounts2024-09-30
260
Bank Of America Corp2024-09-30
28.0
Hanson Mcclain Inc2024-09-30
1.0
Wells Fargo & Co2024-06-30
0.0
Fmr Inc2024-09-30
0.0
Bvf Inc2024-09-30
339.5 K
Vivo Capital, Llc2024-09-30
208.3 K
Note, although Tenax Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tenax Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenax Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenax Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenax Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Mcgauley Thomas over a week ago
Insider Trading
 
Rich Stuart over two weeks ago
Acquisition by Rich Stuart of 100000 shares of Tenax Therapeutics at 0.62 subject to Rule 16b-3
 
Davidson Michael H. over a month ago
Acquisition by Davidson Michael H. of 47500 shares of Tenax Therapeutics at 0.01 subject to Rule 16b-3
 
Davidson Michael H. over three months ago
Acquisition by Davidson Michael H. of 25000 shares of Tenax Therapeutics at 4.5 subject to Rule 16b-3
 
Davidson Michael H. over three months ago
Acquisition by Davidson Michael H. of 2500 shares of Tenax Therapeutics at 3.0 subject to Rule 16b-3
 
Armistice Capital, Llc over three months ago
Acquisition by Armistice Capital, Llc of 4773269 shares of Tenax Therapeutics at 1.0E-4 subject to Rule 16b-3
 
Rich Stuart over three months ago
Acquisition by Rich Stuart of 3581000 shares of Tenax Therapeutics subject to Rule 16b-3
 
Armistice Capital, Llc over six months ago
Discretionary transaction by Armistice Capital, Llc of 3175924 shares of Tenax Therapeutics at 0.903 subject to Rule 16b-3
 
Rich Stuart over six months ago
Disposition of 1909585 shares by Rich Stuart of Tenax Therapeutics subject to Rule 16b-3
 
Armistice Capital, Llc over six months ago
Acquisition by Armistice Capital, Llc of tradable shares of Tenax Therapeutics subject to Rule 16b-3
 
Doogan Declan over six months ago
Disposition of 567871 shares by Doogan Declan of Tenax Therapeutics subject to Rule 16b-3
 
James Mitchum over six months ago
Acquisition by James Mitchum of 500 shares of Tenax Therapeutics subject to Rule 16b-3

Tenax Therapeutics Outstanding Bonds

Tenax Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenax Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenax bonds can be classified according to their maturity, which is the date when Tenax Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Tenax Therapeutics Corporate Filings

F3
6th of December 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
5th of December 2024
Other Reports
ViewVerify
8K
4th of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
26th of November 2024
Other Reports
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.